Advances in Antiviral Drug Design Ebook

Publication: Elsevier Science
 
Is my Device Supported?


Sorry, this ebook is not available for sale. Please take a look at other works by author, or good alternatives from the same category.

Description

The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.

First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.

Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.

Third, as all currently available PIs can be described as “peptidomimetic”, and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.

Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.

Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone “upstream” in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.

Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.

The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

Should you buy this Ebook?

We've put together a collection of resources to help you make a decision regarding whether you should buy this Ebook from us.

  1. Is your device one of these? Ebook reading software will work on the following devices: Windows, Mac, Android 2.2+ Devices, IPad (iOS 3+), IPhone (iOS 3+), Kindle Fire. Several other devices are also supported by the software.
  2. Compare prices. Our price is $142.00. If you would like to research our competitors to see their prices. Here're some places to look:
  3. Why should you buy Ebooks from onlinebookplace.com?

    We've had 1000s of downloads so far and with over 300000+ Ebooks to choose from, onlinebookplace.com is becoming a favorite Ebook Store for many. Allow us to win you over with our competitive pricing, upfront policies and diligent customer service.

    We're Upfront:

    • Every Ebook page on onlinebookplace.com has information on restrictions that publishers have placed on the Ebook along with a clear indication of software required to read the Ebooks.
    • If ratings for an Ebook are available from one of several sources online, then we've attempted to get those to help you make a better purchasing decision about the Ebook. Reviews from Goodreads (a popular reviews site) are provided on the same if they're available.
    • In most cases, we've also attempted to get you links to the Ebook on our competitor's site so that you can compare prices with relative ease.
    • We use McAfee to scan for any vulnerabilities in the system to ensure that any information that you give us does not fall into the wrong hands.
    • We use Paypal, a trusted 3rd party payment provider to accept Payments -- your payment information doen't reside with us. Any information that does end up with us is safe.

Check below for device compatibility and any free 3rd-party software requirements. Choice of what ebook reading app to use is yours, we only present a few common apps that several customers of ours have preferred. You should be able to transfer your purchase to more than one (upto 6) compatible devices as long as your ebook-reading apps have been registered with the same Adobe ID before opening the file.

Computers/laptops/Mac

Windows/Mac PC or Laptop

Free app Adobe Reader required.

Android

Android 2.1+

Most Android devices already have ability to open this format. In case your hardware doesn't, then Adobe Reader may need to be installed.

Kindle Fire (and any Android based Kindle models)

Kindle Should be able to open this format natively.

IPhone/IPad

IPad or IPhone

Most iPhone/iPad devices may already have ability to open this format. In case your hardware doesn't, then Adobe Reader may need to be installed.

Other E-Reader

Several Other devices supported

Most iPhone/iPad devices may already have ability to open PDF or EPub this format. Please refer to your device's documentation to ensure that there is support.

Advances in Antiviral Drug Design